| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Maritimetin targets reactive oxygen species (ROS) and free radicals. It acts as a potent antioxidant by scavenging free radicals, thereby protecting cells and tissues from oxidative damage. Its strong DPPH radical-scavenging activity indicates its effectiveness as an antioxidant.
|
|---|---|
| ln Vitro |
In vitro, maritimetin shows strong DPPH radical-scavenging activity with an IC50 value of 4.12 µM. This potent activity demonstrates its efficacy as a free radical scavenger. The compound is studied for its potential to protect against oxidative stress-related diseases.
|
| ln Vivo |
In vivo, maritimetin is used in the research of cardiovascular disease. Its antioxidant properties suggest potential protective effects against cardiovascular damage caused by oxidative stress. However, detailed in vivo efficacy data are limited and require further investigation.
|
| Enzyme Assay |
Cell-free assays for maritimetin involve measuring its antioxidant activity using the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay. The compound's ability to reduce the DPPH radical is measured spectrophotometrically at 517 nm. The IC50 value is calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for maritimetin involve treating cultured cells with the compound and measuring intracellular ROS levels using fluorescent probes, such as DCFH-DA. The protective effect of maritimetin against oxidative stress inducers, such as H₂O₂, is also assessed.
|
| Animal Protocol |
In vivo animal studies for maritimetin would typically involve oral or intraperitoneal administration in rodent models of cardiovascular disease or oxidative stress. Endpoints include measurements of serum and tissue antioxidant enzyme activities and markers of oxidative damage.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of maritimetin are not extensively reported. As a flavonoid, it is expected to have moderate oral bioavailability and undergo metabolism in the liver. Further studies are needed to characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Available toxicological data for maritimetin are limited. As a naturally occurring compound, it is generally considered to have a manageable safety profile at research doses. Standard toxicity assessments would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Maritimetin is a hydroxyaurone with hydroxyl groups substituted at the 6, 7, 3', and 4' positions. It functions similarly to aurone, acting as a free radical scavenger and a plant metabolite. Maritimetin has been reported to be found in Coreopsis tinctoria, Bidens aurea, and Lasthenia californica, and relevant data are available for reference.
Maritimetin is a research compound with no clinical applications or regulatory approvals. Its primary value lies in its potent antioxidant activity and potential applications in cardiovascular disease research. The compound is a useful tool for studying free radical scavenging mechanisms and the biological activities of aurones. |
| Molecular Formula |
C15H10O6
|
|---|---|
| Exact Mass |
286.048
|
| CAS # |
576-02-3
|
| PubChem CID |
5281292
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.708g/cm3
|
| Boiling Point |
631.5ºC at 760 mmHg
|
| Melting Point |
292 °C
|
| Flash Point |
245.4ºC
|
| Index of Refraction |
1.832
|
| LogP |
2.125
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
447
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1C=C2C(=O)C3=C(O2)C(=C(C=C3)O)O)O)O
|
| InChi Key |
PNIFOHGQPKXLJE-SDQBBNPISA-N
|
| InChi Code |
InChI=1S/C15H10O6/c16-9-3-1-7(5-11(9)18)6-12-13(19)8-2-4-10(17)14(20)15(8)21-12/h1-6,16-18,20H/b12-6-
|
| Chemical Name |
(2Z)-2-[(3,4-dihydroxyphenyl)methylidene]-6,7-dihydroxy-1-benzofuran-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
